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INTRODUCTION
Patients with asthma-COPD overlap have more severe symptoms than those with either asthma or COPD alone, experiencing more frequent and more severe exacerbations and more frequent hospitalizations. This relatively recent interim disease has several phenotypes and consequently different prevalence ranged from 12% -55% of patients of chronic obstructive airway diseases. Despite the considerable prevalence of Asthma-COPD Overlap, few randomized controlled trials have been performed in patients with ACO and a clear management approach is not yet established for ACO (Ding and Small, 2017) .
The goals of therapy of ACOS as a distinct clinical phenotype of COPD are:
1. Relieve symptoms and improve Quality of life (QOL) 2. Improve pulmonary functions and bronchial hyperreactivity 3. Improve and maintain exercise tolerance and physical activities 4. Prevent disease progression and airway remodeling 5. Prevent exacerbation 6. Prevent and treat complications and comorbidities 7. Reduce mortality 8. Prevent adverse effects by therapeutic agent (Kondo and Tamaoki, 2017) In an attempt to improve Asthma-COPD overlap control, the Global Initiative for Asthma updated its recommendations for initial treatment for clinical efficacy and safety as follows:
For patients with features of asthma indicative of chronic airway inflammation: history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. Medical management depends on prescribing adequate controller therapy including inhaled corticosteroids (ICS), but not long-acting bronchodilators alone (as monotherapy). (GINA, 2015) For patients with features of COPD based on a postbronchodilator FEV1/forced vital capacity ratio of less than either 0.70 or the lower limit of normal.and some distinctive clinical phenotypes including chronic bronchitis and/or emphysema. Medical management depends on prescribing appropriate symptomatic treatment with bronchodilators or combination therapy, but not ICS alone (as monotherapy). (Reddel, 2015 and GOLD, 2018) .
For ACO treat with ICS in a low or moderate dose (depending on level of symptoms); add on treatment with long-acting β2 agonist (LABA) and/ or long-acting muscarinic antagonist (LAMA) is usually also necessary. If there are features of asthma avoid LABA monotherapy; all patients with chronic airflow limitation should receive appropriate treatment for other clinical Farrag, Rana, et al Vol. 44, No.1, Dec. 2018 54 problems including advice about smoking cessation, physical activity and treatment of comorbidities.
Non-pharmacological therapeutic modalities include smoking cessation, treatment of comorbid conditions, physical activity, pulmonary rehabilitation, vaccinations, selfmanagement (including a regularly updated action plan) and regular follow-up. Treatment of patients with asthma-COPD overlap involves long-term inhaled corticosteroid (ICS) treatment to reduce the risk of asthma flare-ups. Most patients should also have a trial of a long-acting beta2 agonist (LABA) and/or long-acting muscarinic antagonist (LAMA). The use of LABAs or LAMAs without concomitant ICS should be avoided in patients with any features of asthma, or a history of asthma, because this increases the risk of hospitalisation and death. Management also includes treatment of comorbid conditions. (Bourbea, et al., 2017) The development of Asthma-COPD Overlap syndrome is mainly contributed to patient's susceptibility (host factors) and exposure (environmental factors). " Figure 1 " (Reddel, 2015) . Host factors such as hyperresponsiveness, family history of asthma, and low lung function are common risk factors for asthma and COPD. Environmental tobacco smoke and air pollution are environmental factors of increased interest. Together, a patient's susceptibility (genetic makeup) and exposures (including smoking, infections, pollutants, and diet) contribute to the development of specific molecular or pathologic disease pathways. These interact overtime with the effects of aging, exposures, infections, treatments, and psychosocial factors to produce a range of overlapping clinical phenotypes, which are identified by differing symptoms, physiologic features, and/or biomarkers. At present, we classify these collectively by the terms asthma, COPD, and ACOS; each term represents a heterogeneous collection of conditions expected to have different underlying mechanisms rather than representing a continuum within a single disease. Studying disease processes before the effects of aging and treatment are superimposed would improve the chance of identifying specific modifiable pathways.
The environmental protection agency (EPA) has identified six pollutants as "criteria" air pollutants because it regulates them by developing sciencebased guidelines for setting permissible levels. These six pollutants are carbon monoxide, lead, nitrogen oxides, ground-level ozone, particle pollution (often referred to as particulate matter), and sulfur oxides. Recently, two types of air pollutants have attained increased concern: ozone and particle pollution. Climate change creates conditions, including heat and stagnant air, which increase the risk of unhealthful ozone levels exaggerating the effect of Ground-level Ozone Pollution (EEAA, 2015) .
Particulate air pollution is a complex mixture of solid particles and liquid droplets of different size, composition, and origin suspended in the air.
Particles with a diameter less than 10 µm in aerodynamic diameter are referred to as PM10 and are of special interest because they are inhalable.
Studies on the association between hospital admission and PM10 pollution have shown that PM10 plays a role in the incidence and severity of respiratory disease. PM10 is divided into coarse fraction (>2.5 µm in diameter), which are retained in the upper airways of the respiratory tract and a finer fraction (<2.5 µm in diameter), which is also referred to as PM2.5.
These finer fractions are able to penetrate deep into the respiratory tract and significantly correlated with deaths from cardiopulmonary disease and lung cancer. Different sources contribute to increased particulate matter levels.
Fuel combustion processes in transportation and energy production are the primary sources of the outdoor PM2.5, whereas cooking, smoking, and cleaning activities contribute primarily to the indoor PM2.5 levels. The indoor particulates originate from both indoor and outdoor sources such as traffic-related fine particles penetrating into indoor environments (AbdelSalam, 2013) . Patient education on reducing levels of indoor air pollution is crucial part in management of respiratory diseases.
Clinical pharmacists, as valuable partners in health care team, can play an important role in optimizing Asthma-COPD overlap management through providing adapted pharmacotherapy alongside comprehensive patient education on appropriate medication use and avoidance of airway obstruction triggers including environmental tobacco smoke and air pollutants. Such management approaches have proven to be effective for both asthma and COPD. However, effectiveness of such approaches in patients with Asthma-COPD overlap is yet to be shown in clinical trials (Gibson and McDonald, 2015) . This study compares the effect of Asthma-COPD overlap patient care by clinical pharmacist intervention versus conventional care on disease control.
PATIENTS AND METHODS
Patients signed written information consents for participating in a 2-month ethically approved study was carried out between October 2016 and October 2017 at the outpatient clinics of Ain Shams University Hospitals, Cairo, Egypt (specifically clinic for chest diseases in cooperation with Farrag, Rana, et al Vol. 44, No.1, Dec. 2018 58 immunology department for allergy testing). Patients were randomly assigned to receive conventional care (n=28) or a pre-defined pharmacist intervention (n=26).
Patients were invited to participate in the study provided that they are: fail to shake MDI) were assigned a sum score of zero. technique (failure to remove cap and/or fail to shake MDI) were assigned a sum score of zero; ***patient adherence was assed based on prescription refill rate then patients were categorized as adherent (≥65%) or non-adherent to medication (< 65%).
In the current study, the pharmacist intervention was tailored to the patient's current control state of Asthma-COPD overlap (ACO). By the end of the study, intervention group patients who received clinical pharmacist intervention significantly improved their COPD Assessment Test scores (CAT-score) results than conventional care group. The clinical pharmacist Farrag, Rana, et al Vol. 44, No.1, Dec. 2018 66 intervention patients significantly improved both the inhalation technique and medication adherence, which are both key stones for successful ACO management. Together with reduced use of reliever medication, it seems likely that these clinical improvements result from the more appropriate use of the controller medication. Further assessment of inhalation technique steps showed that the most common errors encountered at baseline were incomplete breath-out all the way, failure to hold breath for 10 seconds after inhalation and repeated inhalation steps for multiple puffs without wait 1-minute in-between. These errors were significantly reduced in the pharmacist intervention group where patients showed better outcomes.
In the present study, almost all patients were prescribed inhaled corticosteroids as controller treatment in the form of beclomethasonesalbutamol combination metered-dose inhalers according to availability and price affordability.
Patients in the intervention arm were 20% more adherent than patients receiving conventional care, suggesting a beneficial impact intervention.
Regarding controller medication use, both inhaled and systemic corticosteroid showed no significant difference between the intervention and conventional care groups. However, intervention patients experience less exacerbations with decreased need for emergency department visits and/ hospitalization than conventional care patients. This suggests that the improvement in symptom control seen in the intervention group can be attributed to beneficial patient education and not to changes in pharmacotherapy.
CONCLUSION
The present study results provide supportive evidence concerning pharmacists' favorable effects on asthma-COPD overlap patient care as evident by improvement in COPD Assessment test (CAT) scores, improved inhalation technique and increased medication adherence. The study results support pharmacists as key members of the health care team.
Study Limitations:
The present study has its limitations. First, the number of patients participated in the study was relatively small compared to other large multicenter studies investigating asthma care programs. However, this can be explained by time constraints and expression of interim phases of asthma-COPD overlap syndrome.
Second, patients participated voluntarily in the study. Therefore, the selected sample may reflect those patients with a stronger interest in adherence to Asthma-COPD care, possibly generating a positive selection bias.
Third, the present study was an open-label study as the intervention necessitates patient education.
Fourth, patients were prescribed salbutamol and beclomethasone inhalers according to availability and price affordability. Unfortunately, combination inhalers with LAMA and/ or LABA were not available in the study setting.
Fifth, the sustainability of beneficial outcomes beyond two months was not assessed.
Recommendations:
The present study supports additive evidence for the effectiveness of the clinical pharmacist's contribution in the care of patients with asthma-COPD overlap (ACO). 
